Download MendeleyPeptides Derived from Vascular Endothelial Growth Factor B Show Potent Binding to Neuropilin-1.
Mota, F., Yelland, T., Hutton, J.A., Parker, J., Patsiarika, A., Chan, A.W.E., O'Leary, A., Fotinou, C., Martin, J.F., Zachary, I.C., Djordjevic, S., Frankel, P., Selwood, D.L.(2022) Chembiochem 23: e202100463-e202100463
- PubMed: 34647407 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1002/cbic.202100463
- Primary Citation Related Structures:
7P5U - PubMed Abstract:
Vascular endothelial growth factors (VEGFs) regulate significant pathways in angiogenesis, myocardial and neuronal protection, metabolism, and cancer progression. The VEGF-B growth factor is involved in cell survival, anti-apoptotic and antioxidant mechanisms, through binding to VEGF receptor 1 and neuropilin-1 (NRP1). We employed surface plasmon resonance technology and X-ray crystallography to analyse the molecular basis of the interaction between VEGF-B and the b1 domain of NRP1, and developed VEGF-B C-terminus derived peptides to be used as chemical tools for studying VEGF-B - NRP1 related pathways. Peptide lipidation was used as a means to stabilise the peptides. VEGF-B-derived peptides containing a C-terminal arginine show potent binding to NRP1-b1. Peptide lipidation increased binding residence time and improved plasma stability. A crystal structure of a peptide with NRP1 demonstrated that VEGF-B peptides bind at the canonical C-terminal arginine binding site. VEGF-B C-terminus imparts higher affinity for NRP1 than the corresponding VEGF-A 165 region. This tight binding may impact on the activity and selectivity of the full-length protein. The VEGF-B 167 derived peptides were more effective than VEGF-A 165 peptides in blocking functional phosphorylation events. Blockers of VEGF-B function have potential applications in diabetes and non-alcoholic fatty liver disease.
- Wolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK.
Organizational Affiliation:
